How PLT012 can Rejuvenate Antitumor Immunity to Reprogram the Immune landscape of Liver Cancer – Cancer Research Institute
Cancer Research Institute (CRI) shared an article on LinkedIn:
“Despite the success of cancer immunotherapies, such as immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors, investigators including CRI Lloyd J. Old STAR Dr. Ping-Chih Ho of Ludwig Cancer Research and University of Lausanne – UNIL describe in a new Cancer Discovery publication.
In response, researchers designed a new antibody based drug, PLT012, which targets CD36 proteins on immune cells in the tumor microenvironment.
Understand how PLT012 can rejuvenate antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with the potential to influence future HCC immunotherapy.”
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.
Authors: Sheue-Fen Tzeng, Yi-Ru Yu, Jaeoh Park, Janusz von Renesse, Huey-Wen Hsiao, Chen-Hsuan Hsu, Josep Garnica, Jintian Chen, Lu-Ting Chiu, Jonas Santol, Tse-Yu Chen, Pei-Han Chung, Lana E. Kandalaft, Patrick Starlinger, Rodney Cheng-En Hsieh, Ming-Chin Yu, Pei-Wen Hsiao, Santiago J. Carmona, Hung-Kai Chen, Zhen Meng, Yun-Han Lin, Jingying Zhou, Chin-Hsien Tsai, Ping-Chih Ho.
You can Read the Full Article on Journal of American Association of Cancer Research.
More posts featuring Cancer Research Institute.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023